Search

RT-qPCR target information. This table provides information on the exact sequences of the primers that were used for RT-qPCR including the Qiagenâ ˘ catalog number. (PDF 29.9 kb)

International audience; Purpose:The aim of this work is to propose a general and simple procedure for the calibration and validation of kilo-voltage cone-beam CT (kV CBCT) models against experimental data.Methods:The calibration and validation of the CT model is a two-step procedure: the source model then the detector model. The source is described by the direction dependent photon energy spectrum at each voltage while the detector is described by the pixel intensity value as a function of the direction and the energy of incident photons. The measurements for the source consist of a series of dose measurements in air performed at each voltage with varying filter thicknesses and materials in front of the x-ray tube. The measurements for the detector are acquisitions of projection images using the same filters and several tube voltages. The proposed procedure has been applied to calibrate and assess the accuracy of simple models of the source and the detector of three commercial kV CBCT units. If the CBCT system models had been calibrated differently, the current procedure would have been exclusively used to validate the models. Several high-purity attenuation filters of aluminum, copper, and silver combined with a dosimeter which is sensitive to the range of voltages of interest were used. A sensitivity analysis of the model has also been conducted for each parameter of the source and the detector models.Results:Average deviations between experimental and theoretical dose values are below 1.5% after calibration for the three x-ray sources. The predicted energy deposited in the detector agrees with experimental data within 4% for all imaging systems.Conclusions:The authors developed and applied an experimental procedure to calibrate and validate any model of the source and the detector of a CBCT unit. The present protocol has been successfully applied to three x-ray imaging systems. The minimum requirements in terms of material and equipment would make its implementation suitable in most clinical environments.

Comparison of hsa-miR-375 levels in the pilot study. The most prominent single miR that could differentiate relapse from control patients was hsa-miR-375 (LIMMA, raw p value 0.009). The box plot shows relapse versus control group, and the expression values of hsa-miR-375 are shown on the y-axis. (PDF 24.3 kb)

Predicted targets of hsa-miR-375 and cancer pathways. Gene enrichment analysis of the predicted targets by GeneCoDis3 software (http://genecodis.cnb.csic.es/). RASD1 was assigned to the PI3K-pathway (http://www.pantherdb.org/pathway/). The numbers on the x-axis indicate how many of the 15 â overlappingâ genes in Additional file 3: Figure S3 are found in a specific pathway. (PDF 20.2 kb)

Target prediction for hsa-miR-375. The Venn diagram shows the number of predicted targets from TargetScan (blue) http://www.targetscan.org/and PITA (red) http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html; 15 genes were suggested by both algorithms. (PDF 44.5 kb)

Comparison of subgroups according to receptor status. This table shows that in ER-Îą+ patients, the levels of hsa-miR-375 are higher than in TNBC and ERÎąâ patients, with fold changes of 1.87 and 4.17. The p value was estimated with the non-parametric Mann-Whitney U test. None of the fold changes is significant. The group of her2-negative patients has slightly higher levels of hsa-miR-375 than the her2-positive patient group, again the difference is not significant. (PDF 124 kb)

Study flow-chart. This additional file shows the various steps of the study. (PDF 42.8 kb)

The term IORT (intraoperative radiotherapy) is currently used for various techniques that show decisive differences in dose delivery. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments with single doses around 10 Gy, providing outstandingly low local recurrence rates in any risk constellation also at long term analyses. Compared to other boost methods, an intraoperative treatment has evident advantages as follows. Precision. Direct visualisation of the tumour bed during surgery guarantees an accurate dose delivery. This fact has additionally gained importance in times of primary reconstruction techniques after lumpectomy to optimise cosmetic outcome. IORT is performed before breast tissue is mobilised for plastic purposes. Cosmesis. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Patient Comfort. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with a 3-week hypofractionated external beam radiotherapy to the whole breast (WBI) is presently tested in the HIOB trial (hypofractionated WBI preceded by IORT electron boost), a prospective multicenter trial of the International Society of Intraoperative Radiotherapy (ISIORT).